Huifeng Bio-Pharmaceutical Technology, Inc. Announces Start up of a New Production Facility.

XI'AN, China -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTCBB: HFGB) the leader in developing and producing plant extracts, pharmaceuticals and pharmaceutical raw materials in mainland China and internationally, announced today the start up of a new production facility in Xi'an, China, which will be processing an initial 1.5 tons of L-Rhamnose with a value of about $100,000 to be exported to the K.F.M. Company in Germany. L-Rhamnose, fermented and extracted from waste materials of Quercetin, is an additive used in a variety of health foods. Other Huifeng products include Troxerutin, Quercetin, Ginko Biloba and Diosmin, manufactured for use as the building blocks of drugs, dietary supplements and as additives in functional foods and beverages.

"This represents a major expansion of the manufacturing capacity for Huifeng," said Jing An Wang, Founder and CEO of Bio-Pharmaceutical Technology, Inc. "We believe that this demonstrates our ability to access foreign markets with our quality products."

U.S. drug and nutraceutical manufacturers' demand for Rutin, Quercertin and Troxeruin is expected to grow by approximately 15% in the next four years, according to industry projections.

About Huifeng Bio-Pharmaceutical Technology, Inc.

Huifeng Bio-Pharmaceutical Technology, Inc. located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of Rutin and related plant-derived chemicals in a class called Flavonoids, with medicinal and other beneficial properties. Founded in 2000, Huifeng uses proprietary patented processes to extract Rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations.

Cautionary Statement Regarding Forward Looking Information

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All readers are encouraged to review the 8-K to be filed in connection with the acquisition discussed above, which outlines risk factors including deal terms and other relevant items. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the companies, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the companies disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.